- Home
- ZLAB vs ATRC Comparison
ZLAB vs ATRC Comparison
Compare ZLAB & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | ATRC |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | ATRC |
|---|---|---|
| Price | $19.20 | $31.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $51.52 | $51.17 |
| AVG Volume (30 Days) | 600.7K | ★ 800.9K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 74.74 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $201,630,000.00 |
| Revenue This Year | $19.06 | $14.90 |
| Revenue Next Year | $18.58 | $12.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.33 | ★ 15.40 |
| 52 Week Low | $15.96 | $28.32 |
| 52 Week High | $44.34 | $43.18 |
Technical Indicators
Market Signals| Indicator | ZLAB | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 33.46 |
| Support Level | $17.00 | $30.06 |
| Resistance Level | $19.70 | $34.59 |
| Average True Range (ATR) | 0.72 | 1.67 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 59.77 | 12.17 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.